Stepping forward in antibody-drug conjugate development-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Stepping forward in antibody-drug conjugate development

Published:2022-01 Issue: Volume:229 Page:107917
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Jin Yiming,Schladetsch Megan A.,Huang Xueting,Balunas Marcy J.,Wiemer Andrew J.

Funder

National Institute of Allergy and Infectious Diseases

University of Connecticut

National Institutes of Health

Herman Frasch Foundation for Chemical Research

National Cancer Institute

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference294 articles.

1. Immunoglobulin G4: an odd antibody;Aalberse;Clinical & Experimental Allergy,2010

2. Antibody-drug conjugates - a perfect synergy;Adair;Expert Opinion on Biological Therapy,2012

3. Phase I study of the anti-CD22 antibody-drug conjugate Pinatuzumab Vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma;Advani;Clinical Cancer Research,2017

4. Tumor stroma as a target in cancer;Ahmed;Current Cancer Drug Targets,2008

5. A phase I study to assess the safety and pharmacokinetics of single-agent Lorvotuzumab Mertansine (IMGN901) in patients with relapsed and/or refractory CD-56-positive multiple myeloma;Ailawadhi;Clinical Lymphoma, Myeloma & Leukemia,2019

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel antibody-drug conjugates based on DXd-ADC technology;Bioorganic Chemistry;2024-10

2. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads;European Journal of Medicinal Chemistry;2024-10

3. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

4. Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system;Scientific Reports;2024-09-13

5. Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges;Molecular Biotechnology;2024-09-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3